Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion study.

ABSTRACT:

Background

In New Zealand, trastuzumab is standard therapy for human epidermal growth factor receptor-2 (HER2)-positive early and metastatic breast cancer. Given the requirement for ongoing adjuvant or maintenance treatment and intravenous (IV) delivery, such a regimen consumes considerable health care resources. The development of a subcutaneous (SC) trastuzumab formulation with a short administration time offers the potential to reduce hospital expenditure. The aim of this study was to determine medical resource utilization associated with administration of trastuzumab SC injection via handheld syringe vs trastuzumab IV infusion in patients with HER2-positive breast cancer in New Zealand.

Methods

This noninterventional, descriptive study was conducted at the outpatient onc

SUBMITTER: North RT 

PROVIDER: S-EPMC4524269 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature